{"filing":{"accession_number":"0001193125-26-288600","cik":"0000034956","ticker":"TENX","company_name":"TENAX THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d251626d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526288600/d251626d8k.htm"},"events":[{"id":14701,"run_id":13095,"accession_number":"0001193125-26-288600","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.9,"summary":"The Board approved amendments to employment agreements for three named executives (Christopher Giordano, Thomas Staab, and Stuart Rich) modifying their severance and change-in-control benefits, including base salary continuation, bonus payments, equity acceleration, and COBRA reimbursements. Concurrently, the Board adopted a Change in Control Plan and a Severance Plan establishing compensatory arrangements for eligible employees with similar benefits.","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12209,"accession_number":"0001193125-26-288600","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on Board-approved amendments to employment agreements for three named executives (Christopher Giordano, Thomas Staab, and Stuart Rich) that modify their severance and change-in-control benefits, including base salary continuation, bonus payments, equity acceleration, and COBRA reimbursements. This is a compensatory arrangement modification under Item 5.02(e), not a departure or appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:41:49.618497+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12210,"accession_number":"0001193125-26-288600","item_number":"8.01","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Board adopted two new plans—a Change in Control Plan and a Severance Plan—that establish compensatory arrangements for eligible employees, including equity acceleration and cash severance benefits. Although the disclosure notes that executive officers are covered by amended individual employment agreements rather than the plans themselves, the core event is the adoption of material severance and change-of-control compensation arrangements. This is a governance-level decision affecting compensation policy and would be material to investors assessing the company's cost structure and executive retention strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:41:49.618497+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12209,"accession_number":"0001193125-26-288600","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on Board-approved amendments to employment agreements for three named executives (Christopher Giordano, Thomas Staab, and Stuart Rich) that modify their severance and change-in-control benefits, including base salary continuation, bonus payments, equity acceleration, and COBRA reimbursements. This is a compensatory arrangement modification under Item 5.02(e), not a departure or appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:41:49.618497+00:00","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-06-29"},{"id":12210,"accession_number":"0001193125-26-288600","item_number":"8.01","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Board adopted two new plans—a Change in Control Plan and a Severance Plan—that establish compensatory arrangements for eligible employees, including equity acceleration and cash severance benefits. Although the disclosure notes that executive officers are covered by amended individual employment agreements rather than the plans themselves, the core event is the adoption of material severance and change-of-control compensation arrangements. This is a governance-level decision affecting compensation policy and would be material to investors assessing the company's cost structure and executive retention strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:41:49.618497+00:00","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-06-29"}]}